🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Joel Greenblatt’s NVO Holdings & Trades

First Buy
Q4 2025
Duration Held
3 Quarters
Largest Add
Q2 2026
+4,758 Shares
Current Position
4,758 Shares
$228,099 Value

Joel Greenblatt's NVO Position Overview

Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 4,758 shares of Novo Nordisk A/S (NVO) worth $228,099, representing 0.00% of the portfolio. First purchased in 2025-Q4, this short-term holding has been held for 3 quarters.

Based on 13F filings, Joel Greenblatt has maintained this position in NVO for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2026, adding 4,758 shares. Largest reduction occurred in Q1 2026, reducing 3,987 shares.

Analysis based on 13F filings available since 2013 Q2

Joel Greenblatt's Novo Nordisk A/S (NVO) Holding Value Over Time

Track share changes against reported price movement

Quarterly Novo Nordisk A/S (NVO) Trades by Joel Greenblatt

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2026 +4,758 New Buy 4,758 $47.94
Q1 2026 -3,987 Sold Out 0 $0.00
Q4 2025 +3,987 New Buy 3,987 $50.88

Joel Greenblatt's Novo Nordisk A/S Investment FAQs

Joel Greenblatt first purchased Novo Nordisk A/S (NVO) in Q4 2025, acquiring 3,987 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Joel Greenblatt has held Novo Nordisk A/S (NVO) for 3 quarters since Q4 2025.

Joel Greenblatt's largest addition to Novo Nordisk A/S (NVO) was in Q2 2026, adding 4,758 shares worth $228,099.

According to the latest 13F filing for Q2 2026, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 4,758 shares of Novo Nordisk A/S (NVO), valued at approximately $228,099.

As of the Q2 2026 filing, Novo Nordisk A/S (NVO) represents approximately 0.00% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.

Joel Greenblatt's peak holding in Novo Nordisk A/S (NVO) was 4,758 shares, as reported at the end of Q2 2026.